Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

t data and treatment protocols every two years.

VELCADE has been available to patients, who have relapsed after a previous treatment, in the United States since 2003 and in Europe since 2004. VELCADE as a single agent shows a median overall survival in this patient population of two and a half years (29.8 months) with "robust response rates" regardless of age. VELCADE in combination with DOXIL(R) was approved in May 2007. Data from a follow-up to a Phase 3 multi-national clinical trial shows that this combination further improves the probability of survival by 41%. Among the findings presented from an open label Phase I/II study evaluating 54 patients, when VELCADE is combined with melphalan and prednisone in newly diagnosed patients who do not go on to have transplants, survival was 85% the strongest 3 year survival rate demonstrated to date.

REVLIMID, an oral drug, is the newest of the novel therapies. This is the first conference since its European approval earlier this month; it is already approved in the United States for use in combination with dexamethasone as a treatment for multiple myeloma in patients who have been previously treated. Among the findings presented, in patients who have relapsed or not responded to a previous treatment, the 35 month median survival using REVLIMID in combination with dexamethasone has been characterized as the "highest response rate and longest overall survival" reported so far from two large randomized controlled Phase III trials that enrolled more than 700 patients worldwide. Importantly, it was previously reported that in patients newly diagnosed with multiple myeloma, in a large randomized Phase III trial evaluating more than 400 patients, REVLIMID with low dose dexamethasone demonstrated what has been called an "unprecedented" 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over.

Combining these two powerful agents, VELCADE AND REVLIMID, produces "robust and du
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:5/24/2013)...  An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...
(Date:5/24/2013)... NEW YORK , May 24, 2013 In ... Takeover Rules and Rule 14e-1 of the United States Exchange ... levels its original offer for Elan Corporation (NYSE: ELN). ... Acquisition Limited ("Royalty Pharma") made an offer for the entire ... Elan Corporation, plc ("Elan") (the "Original Offer").  ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... Presented at 2007 APA Meeting -, COLLEGEVILLE, ... four new studies examining safety and efficacy ... studied as a potential treatment for adults,with ... at the,2007 American Psychiatric Association annual meeting ...
... Childhood Condition, WASHINGTON, May 22, 2007 /PRNewswire-FirstCall/ ... pediatric patients,with gastroesophageal reflux disease (GERD) during ... Disease Week meeting held at the,Washington Convention ... support AstraZeneca's,commitment to research in the area ...
Cached Medicine Technology:New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 2New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 3New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 4New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 5
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout season has officially ... to help prevent grill fires throughout the spring and summer. ... that gas grills led to an average of 7,100 home ... meanwhile, caused approximately 1,200 home fires per year during that ... the following tips from the NFPA to help protect your ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
(Date:5/24/2013)... 2013 Let’s face it: very few are ... for the majority of people to be uncomfortable with the ... a coffee addiction or simply genetics, yellowish or stained teeth ... popular. , Herald Square Dental is proud to ... system: Venus White Max. , Teeth become discolored for ...
(Date:5/24/2013)... The nation’s first trial of a ... da Vinci Surgical System concluded yesterday, Bernstein Liebhard LLP ... Court jury ruled in a 10-to-2 decision that Intuitive ... performed a da Vinci prostatectomy on a patient who ... alleged in their lawsuit that the da Vinci complications ...
(Date:5/24/2013)... May 24, 2013 BestSatelliteProviders.com the ... helped thousands of consumers compare the features and ... reviews site recently released the rankings of the ... are available for viewing on their website. ... , According to Adam Matthews, the spokesperson for ...
Breaking Medicine News(10 mins):Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... ... 2008 SpeechNutrients introduced the supplement NourishLife speak™ which combines omega-3 and ... speech challenges. A recent study published in the July issue ... with verbal apraxia taking a combination of omega-3 and vitamin E ...
... ... Dysport. Dysport is the first rival for Botox. Dr. Pilest met with Medicis CEO Jonah ... who were involved in FDA trials for Dysport. , ... Irvine, CA (PRWEB) August 13, 2009 -- Dr. Nissan Pilest was ...
... , FRANKLIN LAKES, N.J. and LONDON, ... ), the world,s most advanced pharmacy(R) , today extended its ... with United Drug plc, a Pan-European healthcare leader, to provide home-based ... the country,s National Health Service (NHS). The NHS provides healthcare ...
... SILVER SPRING, Md., Aug. 12 The Association ... million in first-year funding through the President,s Emergency Plan ... laboratories and laboratory systems in participating countries. The five-year ... Centers for Disease Control and Prevention (CDC) will support ...
... survivors who lift weights are less likely than their ... arm- and hand-swelling condition that plagues many women following ... Pennsylvania School of Medicine research published in the August ... Medicine . The findings challenge the advice commonly given ...
... , , CHICAGO, Aug. 12 ... comments President Obama continues to make about the high-quality care provided by ... incorrect or not based in fact, we think he does a disservice ... facts about health care reform. We want to set the record ...
Cached Medicine News:Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4Health News:Orange County Derm Nissan Pilest Selected to Become Physician Trainer for Dysport 2Health News:Orange County Derm Nissan Pilest Selected to Become Physician Trainer for Dysport 3Health News:Medco Health Solutions, United Drug Announce U.K. Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions; Innovations to Improve Clinical Quality, Reduce Costs 2Health News:Medco Health Solutions, United Drug Announce U.K. Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions; Innovations to Improve Clinical Quality, Reduce Costs 3Health News:APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 2Health News:Lifting weights reduces lymphedema symptoms following breast cancer surgery, Penn research shows 2Health News:Lifting weights reduces lymphedema symptoms following breast cancer surgery, Penn research shows 3Health News:Statement from the American College of Surgeons Regarding Recent Comments from President Obama 2
... order tips. Each box contains 10,000 tips ... in easy-to-open, re-sealable Bulk Packs of 200 ... with a tamper-proof strip which can easily ... Diamond Tips. Bulk Packs are closed using ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... powerful motor with a lightweight, comfortable design. ... three positions for maximum comfort and convenience.mum ... button on the top of the filler ... wide-angle position is ideal for restricted spaces ...
Medicine Products: